The National Institute on Aging and Alzheimer’s Association (NIA-AA) working group’s updated research criteria delineated 6 progressive clinical stages evident in individuals along the AD continuum, which is identified by the presence of amyloid pathology with or without tau pathology [6]. This evidence concerns the gene MAPT and Alzheimer disease.